Transient Expression Platform: discoCHO

Biologics development often involves a transition from high-expressing transient cells in discovery to stable CHO-K1 cells in manufacturing, which can lead to unpredictable outcomes. ATUM’s discoCHO™ platform solves this by integrating discovery and development phases into a single, CHO-K1-based transient expression system. With discoCHO, therapeutic proteins, including antibodies and enzymes, are rapidly produced in quantities ranging from milligrams to grams, allowing early prediction of Critical Quality Attributes (CQAs) before clinical programs begin. This predictability minimizes manufacturing risks and accelerates timelines, enabling researchers to go from sequence to protein in under four weeks.

Designed for scalability and flexibility, discoCHO facilitates seamless transitions to ATUM’s miCHO stable platform, offering robust titers across volumes and consistent product quality. As a fee-for-service model, it is an accessible solution for companies looking to enhance efficiency and reduce the challenges associated with scaling biologics production. Download the brochure to discover how discoCHO is providing an integrated pathway to achieve success from discovery through to development.